Figure 6.

Workflow of next generation living biobanks (NGLB). Specimens including surgical specimens, core biopsies, needle biopsies, brushed cells, or cells from liquid biopsies (blood, urine, etc.) from patients with disease and/or different stages of disease (for example, before and after treatment, primary or metastatic, etc.) will be collected, cryopreserved, and stored together with their corresponding -omics (genomic, transcriptomic, proteomic, metabolomic, etc.) and clinical information. CR technology will be used to generate an unexhausted cell cultures for living cell banks for future demands in drug discovery, disease modeling, regenerative medicine. CR cells can be used to generate other types of living biobanks such organoids or patient-derived xenografts (PDX) (for tumor).